One of the biggest moments at the annual meeting of the American Society of Clinical Oncology last month came when a drug investigator from M.D. Anderson Cancer Center presented explained that a recent clinical trial for the drug Avastin had left doctors "with no more clarity" about how to treat brain cancer patients than they had before the trial, according to the New York Times.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.